P rompt restoration of blood flow in the occluded epicardial coronary artery by primary percutaneous coronary intervention (PPCI), after an acute ST-segment-elevation myocardial infarction (STEMI), is currently the gold standard therapy for reducing myocardial infarct (MI) size and preserving left ventricular (LV) systolic function.
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cardiovascular magnetic resonance (CMR), 8 but these are typically performed a few hours or days post-PPCI.
Recent studies have shown that invasive coronary physiology measurements acquired during PPCI may be used to assess the coronary microcirculation at the time of PPCI. This may allow early implementation of adjuvant therapies via the intracoronary route to reduce MVO, while the patient is still in the cardiac catheterization laboratory. In this article, we provide an overview of the various invasive coronary physiology techniques to assess the coronary microcirculation in the setting of STEMI and explore their strengths and limitations, and how they could potentially be applied in the clinical setting to improve outcomes.
Determinants and Clinical Significance of MVO
Five major factors have been shown to contribute to the development of MVO namely 9 preexisting coronary microvascular dysfunction, the extent of ischemic injury, the presence of RI, distal coronary microembolization, and individual susceptibility (genetic factors such as 1976T.C polymorphism of the adenosine 2A receptors gene predisposing certain patients to the development of MVO; the presence of preinfarct angina in certain patients may protect against the development of MVO). 9 The preexistence of coronary microvascular dysfunction and individual susceptibility is nonmodifiable. The extent of the ischemic injury is dependent on the onset-to-door and door-to-balloon times, the area-at-risk, Thrombolysis in Myocardial Infarction (TIMI) flow pre-PPCI and collateral flow. Efforts have already been made to reduce the door-to-balloon time to a minimum since the introduction of PPCI. Therefore, the main focus of research to minimize the burden of MVO has been to target both RI and distal coronary microembolization. Many mechanisms have been described to contribute to the occurrence of MVO, and these include external compression of capillaries by interstitial, cellular edema and by swollen cardiomyocytes and endothelial cells, the release of thrombogenic and vasoactive substances, neutrophil plugging, capillary damage with extravasation of red blood cells (leading to intramyocardial hemorrhage [IMH] ), impaired coronary vasodilation, coronary microembolization from the atherosclerotic plaque, in situ thrombosis, and platelet microthrombi as illustrated in Figure 2 . 10,10a IMH has been shown to be a consequence of the process of reperfusion itself. 11 MVO is closely linked to the development of IMH, 12 and clinical studies have supported the notion that MVO precedes the development of IMH in a subset of patients and is considered a more severe form of microvascular injury caused by RI. 13, 14 The presence of MVO after PPCI as assessed by TIMI flow post-PPCI, 15 a combination of ST-segment resolution and myocardial blush grade, 16 myocardial contrast echocardiography, 17 and CMR 18 have all strongly been linked with worse outcomes. 9 In a recent meta-analysis 5 of >1025 STEMI patients reperfused by PPCI and with a CMR performed within the first week, MVO was associated with the occurrence of a composite of cardiac death, congestive heart failure, and myocardial reinfarction with a hazard ratio of 3.74 (95% confidence interval, 2.21-6.34), whereas MI size was not, in a multivariate Cox regression analysis, after adjusting for confounders.
Despite having a patent epicardial coronary artery post-PPCI, those patients with MVO have areas of ongoing hypoperfusion at the microcirculation level, and achieving patency of the microcirculation may theoretically reduce MVO, prevent IMH, and limit MI size. Recently, high-dose intracoronary adenosine and sodium nitroprusside failed to reduce MVO and MI size in a cohort of 247 reperfused STEMI patients. 19 However, 67% of those patients had MVO by CMR, and it is likely that those drugs failed to reach the microcirculation in two third of the patients. Therefore, another approach that would more likely improve outcomes in these patients might be to identify those patients at risk of MVO at the time of PPCI and subject them to low-dose intracoronary thrombolysis 20 first, to achieve patency of the microcirculation, and subsequently treated with an infusion of adenosine or sodium nitroprusside that would then be more likely to reach the microcirculation. (Table 1) , and these are usually performed 3 to 5 days post-PPCI, when it may be too late to intervene. Figure 3 shows an example of a patient with a left anterior descending coronary artery occlusion, reperfused by PPCI with TIMI flow 3, but with extensive areas of MVO (red arrows) on the delayed enhancement CMR images performed on day 3. This imaging modality cannot be performed in most centers immediately post-PPCI, and it may be too late to intervene by the time MVO is identified.
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The coronary microvascular circulation can also be assessed in the cardiac catheterization laboratory with TIMI flow grade, 27 corrected TIMI frame count, 28 TIMI myocardial perfusion grade, 30 and myocardial blush grade 27 (Table  1) . However, these indexes are semiquantitative and can be subjective, 32 although automated software is available. 33 Furthermore, capillary permeability, microvascular spasm, and capillary resistance under resting conditions may influence these indices. 31 Therefore, the suboptimal accuracy of these angiographic methods to detect MVO after PPCI have limited their clinical application.
Invasive Assessment of the Coronary Microcirculation
The coronary circulation can be divided into the epicardial vessels, the microcirculation, and the venous circulation (Figure 2) . 34 Under normal resting physiological conditions, coronary blood flow is maintained at near constant levels over a wide range of perfusion pressures by autoregulation. 35 However, disturbances in the autoregulatory process and impaired microvascular vasodilatory function because of disruption in the coronary microcirculation occurring in the presence of prolonged ischemia and MVO can be detected by invasive measures of coronary microcirculation. This can be divided into flow-based and resistance-based parameters (although 
Flow-Based Parameters
Coronary Flow Velocity Reserve CFVR is an index providing information on both the epicardial and coronary microvascular compartment. It can be derived by using both the Doppler 35 and thermodilution 36 techniques. CFVR is defined as the ratio of hyperemic:resting coronary blood flow. 35 CFVR has been used to assess the coronary microcirculation in the absence of epicardial stenosis. CFVR can also be derived using the thermodilution principle (CFVR=mean transit time [Tmn] at rest/Tmn at hyperemia). 36 A ratio of ≥2.0 is considered normal. 8 A value of <2.0 has recently been shown to have a sensitivity of 79% for MVO and 80% for IMH but with a low specificity of 34% for the detection of both MVO and IMH in a large single-center study of 283 patients. 8 Several studies have shown that CFVR measured in the reperfused infarct-related artery was a potential prognostic marker for LV recovery after STEMI [37] [38] [39] [40] (Table I in the Data Supplement). CFVR has also been shown to correspond well with the extent of MVO by CMR 41 and was found to be a better marker than TIMI flow, corrected TIMI frame count, and myocardial blush grade to predict recovery of LV function. 40 An increase in CFVR from the end of PPCI to 24 hours later was associated with higher myocardial salvage index, whereas a reduction in CFVR at 24 hours was associated with MVO and IMH. 42 A CFVR of <2.1 has also been shown to be associated with increased mortality at 10 years.
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Diastolic Deceleration Time and Systolic Flow Reversal
Rapid deceleration time of coronary diastolic flow velocity (diastolic deceleration time <600 ms) and the presence of early systolic flow reversal in intracoronary Doppler recordings obtained after successful PPCI were shown to be associated with larger extent of MVO and poor long-term outcome after reperfusion.
41,44,45
Resistance-Based Parameters
Intraluminal obstruction (atheroembolization, cellular and humoral factors, etc) in combination with extravascular compressive pathologies (edema and IMH) lead to the increase in microvascular resistance after successful reperfusion achieved by PPCI. Microvascular resistance indices (IMR, HMR, and Pzf) are therefore extremely well suited to determine the extent of the microvascular impairment after PPCI where acute changes in microvascular resistance are expected to be the most dramatic. Moreover, these parameters are specific for the coronary microcirculation during peak hyperemia or zero-flow assumptions and are less likely to be influenced by hemodynamic perturbations such as microvascular tone and resistance, 46 heart rate, 47 and infusion of sodium nitroprusside and dobutamine. 47 
Index of Microvascular Resistance
IMR is derived from the thermodilution principle 48 using a guidewire with a pressure and a temperature sensor and is defined as the distal coronary pressure (Pd) divided by the inverse of the Tmn during hyperemia, or more simply, Pd multiplied by the Tmn (mm Hg·s, or U). 48 The wire sensor is usually positioned in the distal one third of the vessel (>6 cm from guide catheter tip). The average of 3 transit times of 3 mL of room temperature normal saline solution during Usually performed 2 to 7 d postreperfusion when it may be too late to intervene.
CMR is also the gold standard to assess MI size, LV volumes, and ejection fraction.
Not applicable to everyone-eg, those with contraindication to CMR will be excluded.
CMR can also quantify the extent of MVO accurately and differentiate between hemorrhagic and nonhemorrhagic MVO, thereby providing an additional layer of prognostic information. 24 Expensive and not yet widely available.
MDCT MDCT performed immediately after PPCI could detect hypoenhanced areas that were significantly associated with coronary angiographic no reflow. 25 This approach is logistically difficult to implement in most centers.
MDCT performed without contrast reinjection immediately after PPCI for the identification of heterogeneous enhancement could also predict the occurrence of MVO and adverse LV remodeling by CMR. 26 Limited data from 2 studies to date warrant further validation.
TIMI flow A TIMI flow grade of 0-1 in the presence of a patent epicardial coronary artery is indicative of no reflow. 27 Cannot be used to assess the microvascular circulation in those with TIMI flow 3.
cTFC cTFC is a more robust method to assess the epicardial flow quantitatively 28 and is more reproducible.
Requires offline postprocessing.
MBG and TMPG MBG is a measure of maximum contrast intensity, whereas TMPG is a measure of contrast washout time.
Capillary permeability, microvascular spasm, and capillary resistance under resting conditions may influence these indices. 31 MBG has also been shown to predict mortality in patients with TIMI 3 flow 29 and may be more practical.
A normal TMPG has been shown to be a superior marker of death than a TIMI flow of 3 in the thrombolytic era. 30 CMR indicates cardiovascular magnetic resonance; cTFC, corrected TIMI frame count; LV, left ventricle; MBG, myocardial blush grade; MCE, myocardial contrast echocardiography; MDCT, contrast-enhanced multidetector computed tomography; MI, myocardial infarction; MVO, microvascular obstruction; PPCI, primary percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction; and TMPG, TIMI myocardial perfusion grade. Assessing the Coronary Microcirculation in STEMI peak hyperemia is used to calculate Tmn, 49 and the variability among the 3 readings should be <20%. An IMR value <25 U is indicative of normal microvascular perfusion. 50 IMR has been used as a surrogate to invasively assess the coronary microcirculation in STEMI patients for more than a decade (Table I in the Data Supplement). High IMR values at the time of PPCI have been associated with larger MI size by cardiac enzymes, 51 less wall motion recovery at follow-up by echocardiography, 51, 52 and less viability by 18F-fluorodeoxyglucose positron emission tomography. 52 Factors predisposing to high IMR values have not been well studied, but in a small study of 113 STEMI patients, Baek et al 53 found age and symptom-to-balloon time to be major predictors of high IMR.
Several studies have correlated IMR at the time of PPCI and CMR findings. Patients with high IMR were more likely to have MVO, [54] [55] [56] [57] [58] IMH, 59 larger MI size, 54 less myocardial salvage 59 on the acute scan performed within a week, and worse LV function at follow-up. 54 However, not all studies 60, 61 have shown that the IMR at the end of the PPCI procedure could predict MVO on CMR, and this was recently summarized in a meta-analysis of studies reporting mean IMR values only. 62 These studies individually were small and lacked power but after combining data from 6 studies (246 patients) reporting mean IMR values, those with MVO had significantly higher IMR (49±33 U, 99% confidence interval, 41-57 U) than those without MVO (27±22 U, 99% confidence interval, 22-32 U). In a recent single-center study of 283 patients by Carrick et al, 8 IMR was shown to be more closely associated with MVO, IMH and adverse LV remodeling by CMR and clinical outcomes than TIMI myocardial perfusion grade or CFVR.
Data on serial IMR measurements post-STEMI are limited. Sezer et al 63 showed that >33% improvement in IMR in the infarcted territory at 5 months was associated with a 50% reduction in MI size assessed by single photon emission computed tomography in a small cohort of 35 reperfused STEMI patients. Cuculi et al 60 showed that, in 30 patients with CMR data at 6 months, those with MVO had a lower CFVR immediately post-PPCI and at 24 hours and a trend toward higher IMR. At 6 months, there was no difference in IMR and CFVR between these 2 groups of patients, despite a larger chronic MI size in the MVO group. However, unlike Sezer et al, 63 they did not explore the reduction in MI size in those with an improvement in IMR. Most recently, Hoole et al 61 showed in 41 patients that those with an IMR <32 U prestenting had a significant increase in IMR poststenting, and this was attributed to iatrogenic microvascular injury. Serial IMR measurements can improve our understanding of the microcirculation post-STEMI, but because of its invasive nature, getting patients back for repeat invasive measurements in the convalescent/chronic phase is challenging as highlighted by the study by Cuculi et al 60 (almost half of the patients dropped out at 6 months).
Fukunaga et al 58 (88 patients) found that the shape of the thermodilution-derived temperature recovery curve after saline injection could be characterized into 3 categories. Patients in the bimodal group had higher prevalence of MVO on CMR and were at higher risk of death and rehospitalization for heart failure when compared with those in the narrow unimodal and wide unimodal groups. However, the impact of the speed of hand injections and the interobserver reproducibility of these bimodal curves were not assessed and need further validation.
Another approach explored by Park et al 64 (89 patients) has been to stratify STEMI patients according to both IMR and CFVR values. They found that those patients with CFVR <2 and IMR >27 U did not show an improvement in wall motion score index by echocardiography. Ahn et al 56 (40 patients) 
large burden of MVO (red arrows). Assessing the Coronary Microcirculation in STEMI
showed that a combined high IMR (>36 U) and low CFVR (<1.7) were highly predictive of MVO by CMR after PPCI. However, Carrick et al 65 recently showed that combining IMR >40 U with CFVR ≤2.0 did not add prognostic value in 283 patients. All these 3 studies used different cutoff values for IMR and CFVR, and although Carrick et al 65 had the largest number of patients, it was not powered for clinical outcomes.
The effect of IMR on clinical outcomes post-PPCI has been investigated in a large multicenter study of 253 STEMI patients. Fearon et al 66 found an IMR >40 U, measured immediately after PPCI, was the only independent predictor of death (hazard ratio, 4.3; P=0.02) after a median follow-up of 2.8 years. A recent meta-analysis 62 showed that patients with an IMR >41 U at the end of the PPCI procedure were more likely to have MVO on the CMR. Most recently, in a single-center study of 283 STEMI patients, Carrick et al 65 also showed that an IMR >40 U was a multivariable associate of adverse LV remodeling by CMR at 6 months and was a better predictor of all-cause death or heart failure than the duration of ischemia, ST-segment resolution, TIMI myocardial perfusion grade, and CFVR after a median follow-up of 845 days.
However, IMR remains an indirect measure for the coronary microvascular resistance and uses the inverse of transit time as a surrogate for flow. Furthermore, the manual injections of normal saline to obtain the transit times are prone to inter-and intraobserver variability, and not all groups 60, 61 have shown that IMR could differentiate between patients with or without MVO.
Hyperemic Microvascular Resistance
HMR is defined as the Pd divided by mean Doppler flow velocity at peak hyperemia simultaneously measured using a coronary guidewire with a combined pressure sensor and Doppler transducer 67, 68 and measured in mm Hg cm −1 s. A guidewire with a dual pressure and Doppler flow sensor is placed to the distal one third of the infarct-related artery. This dual-sensor guidewire has a Doppler crystal at the tip and a pressure sensor at 1.5 cm from the tip. At hyperemia, phasic coronary flow velocities are obtained from 3 consecutive cardiac cycles and used to calculate the average hyperemic flow velocity.
The role of HMR in STEMI has been less well studied compared with IMR (Table I in the Data Supplement). The availability of a dual pressure and flow sensor wire allows simultaneous pressure and flow measurements within the coronary artery thereby making the measurement of HMR easier. HMR has been shown to be as good as CFVR and diastolic deceleration time at predicting regional wall motion recovery 69 and the transmural extent of MI, 67 but superior to CFVR to predict LV remodeling at 8 months. 70 In a small single-center study of 48 patients, an HMR value >2.5 mm Hg cm −1 s has been shown to be indicative of MVO by CMR (sensitivity of 71% and specificity of 63%) and reduced myocardial blood flow on positron emission tomography. In a larger cohort of 145 STEMI patients, 71 an HMR value >2.82 mm Hg cm −1 s was a strong predictor of a composite of death and rehospitalization for heart failure. However, HMR was measured using the mean aortic pressure rather than the pressure distal to the coronary lesion in that study, and more work with larger number of patients is required to confirm the prognostic significant of HMR immediately post-PPCI.
HMR also remains an indirect measure for the microvascular resistance and uses half the peak Doppler-derived velocity as a surrogate for flow. In addition, detecting an adequate flow signal using a guidewire tipped with both a Doppler flow and a pressure sensor can be technically difficult.
Zero-Flow Pressure
Pzf is defined as the Pd when hypothetically there would be no flow in the coronary artery. Data from several cardiac cycles are used to plot Pd against the peak velocity. There are automated algorithms that can then sample the resultant pressure-velocity loop at the mid-diastolic period of the averaged cardiac cycle. A regression line can then be drawn automatically from the diastolic data points, and Pzf is the pressure at which this line crosses the x axis. This is the extrapolated Pd at which flow would cease in the infarctrelated artery. 46 It provides comprehensive assessment of the microvascular compartment as it assesses coronary flow over a range of pressures, irrespective of cardiac contractility, and may reflect vascular tone. 72 In the context of STEMI, it also provides information on the effect of the interstitial myocardial pressure on the coronary microcirculation. 72 Pzf is derived from pressure-velocity loop analysis, 73 and it informs the operator on the effect of intraventricular and interstitial myocardial pressure (external forces) over collapsible elements (capillaries) of the microcirculation. Therefore, Pzf measured after PPCI can be expected to be dependent mainly on the extent of external microcirculatory compression by edema and IMH. After PPCI, microvascular impairment may be partly attributed to decrease in total cross-sectional microvascular area by compressive effect generated by edema and IMH. In addition, in patients with STEMI, increased diastolic filling pressures because of increased cardiac muscle stiffness caused by cellular and interstitial edema may also decrease intramyocardial vascular capacitance and limit coronary flow in late diastole. Therefore, the transmitted increase in intracavity and interstitial pressures contributes to external compression of microcirculation and results in increased Pzf.
In small proof-of-concept studies, Pzf was a better predictor of viability by 18F-fluorodeoxyglucose positron emission tomography than CFVR (27 patients), 73 was associated with higher LV filling pressures (68 patients) 72 and adverse LV remodeling (48 patients), 74 and was a better predictor of chronic MI size by CMR than HMR and IMR (34 patients). 46 However, Pzf was not found to be superior to CFVR, Pzf, and diastolic deceleration time in predicting the transmural extent of MI by CMR performed at 13 days (27 patients). 67 To date, only 1 study has evaluated Pzf and MVO by CMR, and a cutoff value of 42 mm Hg for Pzf did not differentiate those with and without MVO. 46 As summarized in Table 2 , Pzf requires offline postprocessing, and the automated algorithms for its interpretation are not widely available yet. Therefore, this index currently remains a research tool.
Current Applications
IMR has already been used as a surrogate end point in several proof-of-concept studies aiming to improve the coronary microcirculation in reperfused STEMI patients (Table II in the Data Supplement). The impact of strategies such as intracoronary streptokinase administered immediately after PPCI, 20 nicorandil, 77 sodium nitroprusside, 78 distal protection device, 79 thrombus aspiration, 61 and a combination of intracoronary abciximab and aspiration thrombectomy 57 on IMR has been investigated in small proof-of-concept studies, and there are several other studies that are ongoing (Table II in Hypothetically, in an ideal study, invasive coronary measurement with a reliable marker at the end of the PPCI procedure would identify those patients with MVO with high sensitivity and specificity. Given that MVO is because of a combination of factors, these patients would then be randomized to a combination therapy with intracoronary thrombolysis (to achieve patency of the microcirculation) and an intracoronary The Doppler flow velocity tracings may not be consistent from beat to beat and could be a source of variability. CFVR can also be derived using the thermodilution principle (CFVR=Tmn at rest/Tmn at hyperemia). 36 CFVR is unable to distinguish between relative epicardial and microvascular contribution to total coronary resistance. A ratio of ≥2.0 is considered normal.
CFVR is dependent on hemodynamic factors (ie, blood pressure, heart rate, etc).
When using the thermodilution technique, manual injection of the saline can be a source of variability.
Requires the achievement of hyperemia. In the STEMI setting, using adenosine may be ineffective in those patients who may have consumed caffeinated products.
IMR Defined as Pd divided by the inverse of the Tmn during hyperemia, or more simply, Pd multiplied by the Tmn (mm Hg·s, or U). 48 Manual injection of the saline can be a source of variability.
The wire sensor is usually positioned in the distal one third of the vessel (>6 cm from guide catheter tip).
The average of 3 transit times of 3 mL of room temperature normal saline solution-the variability should be <20%-during peak hyperemia is used to calculate mean Tmn. 49 An IMR value <25 U is indicative of normal microvascular perfusion.
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IMR has been shown to be more reproducible than CFVR and to be independent of hemodynamic influences (pacing at 110 bpm, nitroprusside infusion or dobutamine infusion). 47 It is not affected by epicardial stenosis. 48 In the presence of collaterals, corrected IMR (cIMR) using the formula cIMR=Pa×Tmn×(Pd−Pw)/(Pa−Pw) is more accurate as this takes into account the contribution of collateral flow. 75, 76 HMR HMR is derived as the ratio of distal coronary pressure and hyperemic flow velocity 67 and measured in mm Hg cm −1 s.
The Doppler flow velocity tracings may not be consistent from beat to beat and could be a source of variability.
A guidewire with dual pressure and Doppler flow sensor is placed in the distal one third of the infarct-related artery.
Requires the achievement of hyperemia. In the STEMI setting, using adenosine may be ineffective in those patients who may have consumed caffeinated products. At hyperemia, phasic coronary flow velocity are obtained from 3 consecutive cardiac cycles and used to calculate the average hyperemic flow velocity.
Pzf
Pzf is defined as the distal coronary pressure when hypothetically there would be no flow in the coronary artery.
Does not require hyperemia. Requires offline postprocessing.
Data from several cardiac cycles are used to plot Pd against the peak velocity. There are automated algorithms that can then sample the resultant pressure-velocity loop at the mid-diastolic period of the averaged cardiac cycle. A regression can then be drawn automatically from the diastolic data points, and Pzf is the pressure at which this line crosses the x axis. This is the extrapolated distal coronary pressure at which flow would cease in the infarct-related artery. 46 CFVR indicates coronary flow reserve; HMR, hyperemic microvascular resistance; IMR, index of microvascular resistance; Pa, aortic pressure; Pd, distal pressure; Pzf, zero-flow pressure; Pw, wedge pressure; STEMI, ST-segment-elevation myocardial infarction; and Tmn, mean transit time.
vasodilator with anti-inflammatory properties such as adenosine (which could be continued intravenously on the ward) or placebo. The primary end point of interest should ideally be hard clinical outcomes such as cardiovascular death and hospitalization for heart failure. However, such a study would require a large number of patients and end points such as the extent of IMH, MVO, and MI size by CMR 3 days later, and adverse LV remodeling at 6 months could be used as surrogates. Table 2 summarizes the limitations of the current invasive markers to assess the microcirculation discussed to date. Future studies should aim at addressing these limitations in the first instance. Some examples would be as follows:
Limitations of Current Invasive Markers and Future Directions
1. To explore the possibility for an automated method (eg, using a pump injector) to inject the 3 mL of normal saline to minimize operator-related errors and improve interobserver and intersite reproducibility when performing IMR measurement. 2. Further validation work is required to assess the performance of HMR to detect MVO by CMR before it can be used to assess the effectiveness of therapies. Moreover, improvement in the delivery profile of the Doppler wire would increase the use of this technique in future studies. 3. The derivation of Pzf is based on the extrapolation from the pressure-velocity loop, and the analysis techniques are time-consuming and are not available for immediate read-outs of Pzf. Therefore, more work remains to be done to make the analysis of fully automated and the Pzf read-outs to be immediately available at the time of PPCI, before it can be widely used. 4. Limited data are available on the strength of diastolic deceleration time and systolic flow reversal to identify MVO when compared with IMR, HMR, and Pzf. Therefore, further, adequately powered, comparative studies using these parameters, using a multicenter approach to facilitate recruitment, are needed. These above steps would help to assess which of these markers would emerge as the most robust surrogate marker for predicting MVO at the end of the PPCI procedure. Early identification of these high-risk patients is important as already described above, and early adjuvant intervention could then be started in the cardiac catheterization laboratory and administered via the intracoronary route and continued intravenously in the ward if needed. Therapies that may be beneficial in this setting would be glycoprotein IIb/IIIa inhibitors (eg, abciximab 80 to reduce platelet aggregation in the microcirculation), thrombolytics (eg, half dose alteplase for lysis of distal embolization of thrombi), vasodilators (eg, adenosine 19, 81 and nicorandil 77 for spasm of the microcirculation due to release of vasoactive substances), and anti-inflammatory agents (eg, methylprednisolone 82 to reduce reperfusion edema and relieve extrinsic compression of the microcirculation). Other treatments aiming to stabilize the endothelium with angiopoietin-1 or tyrosine kinase inhibitors 13 may help to reduce extravasation of red blood cells and the development of IMH. Using this approach would also avoid any adjuvant strategies be given to those patients who are unlikely to have MVO and minimize their exposure to potential adverse events. Figure 4 shows a hypothetical approach in future studies to identify and target those at high risk at the end of the PPCI procedure using IMR as an example. Given that patients with an IMR of >40 U have been shown to more likely have MVO 62 and worse outcomes, 65, 66 this value could be used as a cutoff. Those patients with an IMR of >40 U at the end of PPCI could then be targeted with further adjuvant therapies mentioned above, and this approach may improve outcomes in this group of patients.
Conclusions
Invasive assessment of the coronary microcirculation at the time of PPCI is an exciting field that could provide us with the opportunity to interrogate the extent of the microvascular injury reliably in the cardiac catheterization laboratory despite having a patent infarct-related epicardial coronary artery. This approach would potentially identify those patients at high risk of MVO and target them with adjuvant therapies. However, more validation work remains to be done before one or a combination of these invasive markers described here could be used in therapeutic trials aiming to eventually improve outcomes in these patients. 
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Figure 4.
A hypothetical approach to identify the patients at high risk of developing microvascular obstruction (MVO) using index of microvascular resistance (IMR). This algorithm shows that IMR could be used in those with thrombolysis in myocardial infarction (TIMI) flow 3 grade at the end of the primary percutaneous coronary intervention (PPCI) to further identify those who would benefit from further adjuvant intracoronary therapies.
